BOSTON and JERUSALEM, April 20, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced that Ron Mayron has joined its Board of Directors. Mr. Mayron is taking the seat of Zeev Bronfeld, a Founder of

BOSTON and JERUSALEM, Israel, April 15, 2021 (GLOBE NEWSWIRE) --  Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of veteran finance and operations executive Ramesh Ratan as U.S. Chief Financial Officer.

BOSTON and JERUSALEM, April 06, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the Company will deliver a poster presentation titled “Pharmacokinetics of an Oral Human Growth Hormone (hGH)

‒ Achieved Primary Endpoint in EB613 Phase 2 Clinical Trial ‒ ‒ Final Data , Including Bone Mineral Density, Expected in Q2:21 ‒ ‒ FDA Approv al of EB613 IND for the Treatment of O steoporosis Enables Initial U.S. Clinical Trial ‒ ‒ Amgen Collaboration Continues to Progress ; Company Evaluating

BOSTON and JERUSALEM, March 11, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and financial results for the year ended December 30, 2020 on March 18, 2021, before the U.S.

‒ Trial Met Primary Endpoint of Significant Increase in P1NP Based on Final Analysis of 3 Month Data ‒ ‒ Final Analysis of 6-Month Data , Including Change in Bone Mineral Density, Expected in Q2:21 ‒ BOSTON and JERUSALEM, March 11, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd.

BOSTON and JERUSALEM, March 04, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will participate in the H.C. Wainwright Global Life Sciences Conference.

‒ EB612 When Added to Standard of Care Led to a Statistically Significant Decrease in  Supplemental Calcium Usage – ‒ Oral Human Parathyroid Hormone (1-34) Has the Potential to Have a Major Impact on Compliance, Adherence, Therapeutic Impact and Quality of Life for Patients – BOSTON and JERUSALEM,

‒ Program Leverages Entera’s Platform for Potential Development of Oral GLP-2 Analogs for Gastrointestinal and Other Indications ‒ ‒ GLP-2 Analogs Currently Administered Via Daily Injection to Treat Short Bowel Syndrome ‒ BOSTON, Mass. & JERUSALEM, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd.

BOSTON and JERUSALEM, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today issued a Letter to Shareholders from Spiros Jamas, Sc.D, its newly appointed Chief Executive Officer and a member of its Board